UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric patients with B-cell NHL and patients in primary relapse.

Trial Details

NCT ID
NCT04544592
Phase
PHASE1 / PHASE2
Sponsor
University of Colorado, Denver
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
Locations (sample)
  • Aurora, Colorado, United States|39.72943,-104.83192

Key Eligibility Criteria

  • Meets clinical criteria for leukapheresis or has a leukapheresis product previously collected and stored per recommended guidelines.
  • Provision of signed and dated consent form from parent or guardian (patients \<18), the patient themselves (\>18), or legally authorized representa…
  • Willingness to participate in long term follow up study.
  • Stated willingness to comply with all study procedures and be available for the duration of the study.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →